Filing Flows › Health Care › Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics (IMDX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Insight Molecular Diagnostics (IMDX) Q2 2026 earnings results →
Q2 2026 Revenue down 54% year over year to $239K
Insight Molecular Diagnostics made $239K in Q2 2026 (-54% Y/Y): Laboratory Services $218K, Kitted Products $21K. Operating margin n/m, net loss $11.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $239K in Q2 2026, down 54% year over year and up 647% from the previous quarter. Laboratory Services was the largest line at 91% of revenue. Laboratory Services lost $276K year over year (down 56%), 99% of the total change.
Gross margin was 65.7%, up 0.4 points from Q2 2025. Operating costs exceeded revenue by $11.4M, an operating margin of -4770.7%. Operating expenses grew 14% against a revenue fall of 54%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $11.3M, wider than the previous quarter's $4.3M loss.
Operating cash flow was −$9.3M. Non-cash charges added back $665K of depreciation and amortization and $661K of share-based compensation. Working capital and other items added $666K. Capital expenditures of $779K exceeded it, leaving free cash flow of −$10.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $239K | -54% | n/m | −$11.3M | −$9.3M |
| Q1 2026 | 10-Q | May 13, 2026 | $32K | -98% | n/m | −$4.3M | −$7.6M |
| Q4 2025 | 10-K | Mar 26, 2026 | $1.1M | -23% | n/m | −$23.0M | −$5.5M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $260K | +126% | n/m | −$10.9M | −$4.6M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $518K | +398% | n/m | −$9.7M | −$6.2M |
| Q1 2025 | 10-Q | May 12, 2025 | $2.1M | 12× | -318.0% | −$6.7M | −$5.8M |
| Q4 2024 | 10-K | Mar 24, 2025 | $1.5M | +373% | n/m | −$33.5M | −$5.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Insight Molecular Diagnostics
We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which we believe can improve standards of care while also creating demand for more testing. We believe that combining innovative science with a simple, but disruptive, business model can create substantial value. Our initial targeted customer institutions are hospitals, transplant centers and labs.
In its own words, from its 10-K, filed Mar 26, 2026.
Insight Molecular Diagnostics against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -54% against the peers' median +2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IMDX Insight Molecular Diagnostics | Q2 2026 | $239K | -54% | n/m |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Insight Molecular Diagnostics 10-Q on SEC EDGAR · CIK 1642380 · In Vitro & In Vivo Diagnostic Substances
13F: who owns IMDX and who is buying
More on IMDX
- How Insight Molecular Diagnostics makes money: revenue by segment
- Insight Molecular Diagnostics next earnings date and what analysts expect
- Insight Molecular Diagnostics stock forecast, price target and fair value
- Who owns Insight Molecular Diagnostics stock: holders, funds and Congress trades
- Insight Molecular Diagnostics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
Compare IMDX with
- Insight Molecular Diagnostics vs Biomerica (IMDX vs BMRA)
- Insight Molecular Diagnostics vs Volitionrx (IMDX vs VNRX)
- Insight Molecular Diagnostics vs Aspira Women's Health (IMDX vs AWHL)
- Insight Molecular Diagnostics vs Celldex Therapeutics (IMDX vs CLDX)
- Insight Molecular Diagnostics vs Cardio Diagnostics Holdings (IMDX vs CDIO)